Pharmaceutical

Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology by ImmunityBio for Non-Small Cell Lung Cancer: Likelihood of Approval

Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology is under clinical development by ImmunityBio and currently in Phase I for Non-Small Cell Lung Cancer.

Feb 8, 2024 - 18:00
Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology is under clinical development by ImmunityBio and currently in Phase I for Non-Small Cell Lung Cancer.
Read the original article

Tags:

Previous Article

(Edetate disodium + ethyl alcohol + minocycline hydrochloride) by Citius Pharmac...

Next Article

Vorolanib by EyePoint Pharmaceuticals for Diabetic Macular Edema: Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Aquestive Therapeutics gets grant for enhanced pharmace...

Aug 23, 2024

STAT+: Amputees have better balance, less pain after electrical stimulation, study finds

STAT+: Amputees have better balance, less pain after el...

Dec 15, 2023

Women spend 20% more per year on out-of-pocket health costs, says report

Women spend 20% more per year on out-of-pocket health c...

Sep 30, 2023